If efficacy is proven to increase from the gemcitabine combo does escalation then I’d say it’s safe to say larger pharma companies would start looking at us. Gemcitabine is the standard care for pancreatic cancer, so we have the potential to capture a wide range of market when you consider using in combo… another 12-18 months this ticker maybe very different MC
Ann: Change of Director's Interest Notice - Dr Christopher Burns, page-5
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
